A Randomised, Double Blind, Placebo-controlled Phase II Multicentre Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects with Acute Ischemic Stroke
Lead PI: Dr Bruce Campbell
Status: Recruiting Closed.
No. of Patients Currently Recruited: 100 No. of Patients Required: 100
ReMEDY is a randomised, double-blind, placebo-controlled Phase II multicentre study to assess the safety and tolerability of DM199 (a recombinant human version of the Kallikrein-1 protein) administered intravenously and subcutaneously in subjects with acute ischemic stroke through 90 days.